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Abstract
Background: Pioglitazone, an oral anti-diabetic that stimulates the PPAR-gamma transcription factor, increased survival of
mice with amyotrophic lateral sclerosis (ALS).
Methods/Principal Findings: We performed a phase II, double blind, multicentre, placebo controlled trial of pioglitazone in
ALS patients under riluzole. 219 patients were randomly assigned to receive 45 mg/day of pioglitazone or placebo (one: one
allocation ratio). The primary endpoint was survival. Secondary endpoints included incidence of non-invasive ventilation
and tracheotomy, and slopes of ALS-FRS, slow vital capacity, and quality of life as assessed using EUROQoL EQ-5D. The study
was conducted under a two-stage group sequential test, allowing to stop for futility or superiority after interim analysis.
Shortly after interim analysis, 30 patients under pioglitazone and 24 patients under placebo had died. The trial was stopped
for futility; the hazard ratio for primary endpoint was 1.21 (95% CI: 0.71–2.07, p = 0.48). Secondary endpoints were not
modified by pioglitazone treatment. Pioglitazone was well tolerated.
Conclusion/Significance: Pioglitazone has no beneficial effects on the survival of ALS patients as add-on therapy to riluzole.
Trial Registration: Clinicaltrials.gov NCT00690118.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a lethal neurological
disease with limited therapeutic options. Only riluzole demon-
strated efficacy in prolonging survival of ALS patients [1].
Inflammatory mediators are heavily produced in the CNS of
ALS patients, and decreasing inflammation is protective in mouse
models of ALS [2].
Pioglitazone is an oral anti-diabetic that stimulates the
transcriptional activity of peroxisome proliferation activated
receptors (PPARs), most notably of the PPAR subtype. Pioglita-
zone possesses anti-inflammatory properties that might be
beneficial in ALS patients [3]. Interestingly, three independent
groups reported beneficial effects of pioglitazone in ALS mouse
models associated with decreased levels of inflammatory mediators
[4,5,6]. Pioglitazone displays pleiotropic effects on energy metab-
olism through insulin sensitization, decreased glycaemia, and
decreased circulating levels of liver enzymes and has been shown
to be safe even in non-diabetic patients [7,8,9,10]. A widely
documented side effect of pioglitazone is a robust (3–5 kg) weight
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gain dependent upon neuronal, presumably hypothalamic, PPAR-
c receptors [7,8,9,10,11,12]. These metabolic effects, and espe-
cially weight gain, might be clinically relevant for ALS since
rescuing energy deficit in animal models alleviates neurodegener-
ation [13]. Furthermore, moderate obesity [14] and hyperlipemia
[15,16] have been associated with improved survival in ALS,
suggesting that increased weight gain might be protective.
In all, pioglitazone represented a candidate drug able to act
through multiple protective mechanisms. Here, we sought to test
whether pioglitazone is beneficial in ALS by performing a phase
II, multicentre, stratified, parallel-group, placebo-controlled trial
of pioglitazone in ALS to assess the potential efficacy of
pioglitazone as an add-on therapy to riluzole on survival as a
primary endpoint. Incidence of non-invasive ventilation (NIV) and
tracheotomy, and slopes of revised ALS functional rating scale
(ALS-FRS-R), slow vital capacity (SVC), and quality of life (using
EUROQoL EQ-5D; http: www.euroqol.org) were secondary
endpoints.
Methods
This phase II clinical trial was designed as a multicentre,
stratified, parallel-group, placebo-controlled trial of pioglitazone in
patients with ALS as an add-on therapy to riluzole. The trial
protocol can be accessed at http://www.clinicaltrials.gov
(NCT00690118). This protocol and supporting CONSORT
checklist are available as supporting information; see Checklist
S1 and Protocol S1.
Participants
Patients with possible, probable (clinically or laboratory-
supported) or definite ALS according to the revised version of
the El Escorial World Federation of Neurology criteria were
considered for enrolment into the study. Included patients
displayed onset of progressive weakness within 36 months prior
to study and had a disease duration of more than six months and
less than three years (inclusive) with disease onset defined as date of
first muscle weakness, excluding fasciculation and cramps. They
reached a best-sitting SVC between 50% and 95% of predicted
normal. They were capable of thoroughly understanding the
information provided and giving full informed consent. Included
women of childbearing age were non-lactating, and surgically
sterile, or used a highly effective method of birth control, and had
a negative pregnancy test. All included patients had been treated
with 100 mg riluzole daily for at least three months prior to
inclusion.
Exclusion criteria were: Participation in another clinical study
within the preceding 12 weeks; tracheotomy or assisted ventilation
during the preceding three months; gastrostomy; any medical
condition known to have an association with motor neuron
dysfunction which might confound the diagnosis of ALS; presence
of any life-threatening disease or impairment likely to interfere
with functional assessment; confirmed hepatic insufficiency or
abnormal liver function (ASAT and/or ALAT .1.5 upper limit of
normal); renal insufficiency (serum creatinine .2.26 mg/dL);
evidence of major psychiatric disorder or clinically evident
dementia; known hypersensitivity to the study drugs; patient likely
to be not cooperative, not comply with the trial requirements (as
assessed by the investigator), or unable to be reached in
emergency; use of other antidiabetic drugs; heart failure, or
history of heart failure (NYHA I to IV); history of macular
oedema; treatment with thiazolidinediones within three months
prior to screening; known or suspected history of alcohol and/or
drug abuse; treatment with gemfibrozil within three months prior
to screening.
Ethics
All patients gave written informed consent. The ethics
committee of the University of Ulm approved the study protocol.
Interventions
The two treatment groups were 100 mg riluzole plus 45 mg
pioglitazone (pioglitazone group), and 100 mg riluzole plus
placebo (placebo group).
After inclusion, patients underwent a four-week screening
phase, and a treatment phase (18 months). The dosage was
increased stepwise: 15 mg once daily (od) during the first two
weeks, 30 mg od during week three and four and 45 mg od from
week five. Clinical and physical examinations, blood sampling,
and drug compliance were recorded at on-site visits (1, 2, 6, 12 and
18 months after baseline visit). Body weight, and functional status
(including NIV and ALS-FRS-R) were also recorded at 9 and 15
months after baseline visit through telephone contacts. The
investigator observed patients for adverse events (AEs), and
instructed patients to report any events. A period of 14 days for
follow-up of AEs after the patient had routinely or prematurely
terminated the study was performed additionally.
Objectives
We sought to test whether pioglitazone 45 mg daily is beneficial
in ALS patients under riluzole.
Outcomes
The primary endpoint was survival time, i.e. time between
inclusion in the study and death or last patient contact. Secondary
efficacy outcomes were incidence of tracheotomy, and of NIV
during study period, ALSFRS-R, and its changes, Quality of life
using the EUROQoL EQ-5D and its changes.
Sample Size
Sample size was calculated according to a previously published
clinical trial in ALS [17]. The study was conducted using a two-
stage group sequential test design within the D-class of critical
values [18] with possible sample size adaptation after the planned
interim analysis. A p-value of 0.5 was assumed as stopping for
futility bound in interim analysis. For sample size calculation the
following assumptions were made: One-sided alpha= 0.025 and
18-month survival rates of 60% in the placebo group and 78% in
the pioglitazone group (hazard ratio = 0.486) [17], the statistical
power is 80% if the log-rank test is performed after observation of
31 deaths at the first stage and after 62 deaths at the second stage
according to the formula of Schoenfeld (using ADDPLANH
version 3.1.2, ADDPLAN GmbH, Germany).
Pioglitazone was originally developed as oral antidiabetic drug
and clinical trials showed that pioglitazone was well tolerated. At
present, it has been prescribed to over 3.5 million patients. Thus,
the use of a one-sided statistical test for primary efficacy analysis
was considered as acceptable. Assuming an accrual time of six
months, a treatment period of 18 months, and a constant accrual
rate, a total of 176 subjects (88 subjects per group) was expected to
yield the necessary number of deaths. Under these assumptions,
the time points of analyses were expected to be 12.3 month’s
observation time (interim analysis) and 24 months observation
time (final analysis). Considering a dropout rate of 10%, inclusion
of 196 patients was planned.
Pioglitazone in ALS
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Randomization- sequence Generation, Allocation and
Implementation
At the randomisation visit, each patient eligible for study
participation was randomised to one of the two treatment groups,
and received the next consecutive randomisation/patient number
according to her/his stratum from a block of randomisation
numbers per site. The code was broken only for interim analysis,
and at the end of study.
Haupt Pharma Brackenheim GmbH (Brackenheim, Germany)
generated the randomisation list. Block-randomisation with a
block size of four was performed. A pseudo-random number
generator ensured that the resulting treatment sequence was
reproducible. Patients were assigned to their stratum according to
the location of the earliest ALS symptom. Patients with
simultaneous spinal and bulbar onset were defined as bulbar.
Cervical and respiratory onsets were stratified to the spinal-onset
stratum.
Blinding
The trial was double-blinded. Study medication was packed and
blinded by Haupt Pharma Brackenheim.
Statistical Methods
The study population was analysed according to the intention-
to-treat principle. All randomized patients who received at least
one intake of study medication were analysed for efficacy and
safety.
To investigate efficacy, the unstratified log rank test was used to
compare groups. The statistical hypotheses in terms of the hazard
ratio were the following:
H0: l2/l1.=1 (i.e. identical or poorer survival in the
pioglitazone group).
H1: l2/l1,1 (i.e. better survival in the pioglitazone group),
Where l2/l1 is the hazard ratio, l1 denotes the hazard in the
placebo group; l1 denotes the hazard in the pioglitazone group.
The overall type-I-error rate was set at a=0.025 (one-sided).
For comparison of baseline characteristics, we performed group
comparisons using Mann-Whitney test for continous items and x2
test for binary outcomes. Binary secondary outcomes (incidence of
tracheotomy or NIV) were calculated both as total number and as
percentage including the 95% confidence interval and group
comparisons were performed using the x2 test. For continuous
secondary outcomes (ALSFRS-R, EUROQoL EQ-5D) group
comparisons were performed using mixed effects regression model
analysis. All secondary endpoints were analysed descriptively. All
statistical tests performed were two-sided at a significance level of
5%. All results from analysis of the secondary endpoints were
regarded as hypothesis generating only, and not as proof of
efficacy.
An independent statistician performed the interim analysis at
July 17th 2009 at the Institute of Epidemiology and Medical
Biometrics at the University of Ulm. The interim analysis was
performed with data from all available patients on June 10th, 2009
(197 patients, pioglitazone n= 99, placebo n=98). Interim analysis
was initially planned after observation of 31 deaths. However,
because of the unexpected low number of deaths from start of trial
until March 2009, the protocol was amended to perform the
interim analysis either after observation of a total of 31 deaths or in
June 2009, depending on what condition happens first. Statistical
analyses were performed at the Institute of Epidemiology and
Medical Biometrics at the University of Ulm using the statistical
software package SAS Version 9.2 under Windows.
Results
Participant Flow and Recruitment
Between the 29th of May 2008 and the 14th of August 2009, 219
ALS patients were enrolled, and randomly allocated to either
placebo (n= 110; bulbar: n = 33, spinal: n = 77), or pioglitazone
(n= 109; bulbar: n = 32, spinal: n = 77) treatment after stratifica-
tion based on site of onset (bulbar or spinal). One patient in the
placebo group did not take any dose of study medication and was
therefore excluded from the study. Figure 1 shows the study flow
chart.
Baseline Data
Baseline characteristics of both groups were similar (Table 1). In
particular, both groups of patients showed similar sex ratio, age
and functional status as measured by revised ALS functional rating
scale (ALSFRS-R) and slow vital capacity (SVC, a measure of
respiratory function). Since energy metabolism is a modifyer of
ALS disease [19] and pioglitazone interferes with energy
metabolism, we also monitored BMI, glycaemia, circulating liver
enzymes (ASAT and ALAT) and found these different parameters
similar at inclusion between both groups (Table 1). Blood pressure
showed a trend to be higher in the pioglitazone group.
Primary Outcome
In interim analysis, which was performed about one year after
start of recruiting patients, we observed death of 24 patients, 14 in
the pioglitazone group and 10 in the placebo group. There was no
difference between pioglitazone group and placebo group. Since
the number of deaths was unexpectedly low, the data monitoring
and safety committee (DMSC) requested continuation of the trial.
Number of deaths and death rate were provided monthly and the
DMSC recommended to stop the trial for futility on the 28th of
April 2010 due to the increased death rate in the pioglitazone
group (pioglitazone, 30 deaths; placebo, 24 deaths). In final
statistical analysis, the hazard ratio was 1.21 (95%CI: 0.71–2.07,
p=0.48). This means that the hazard for death was increased of
21% in the pioglitazone group and the difference between both
groups was not significant. The comparison of survival curves for
both treatment groups showed no difference in survival (Figure 2).
Secondary Outcomes
Secondary variables for efficacy were also non-significantly
affected by pioglitazone treatment. ALS-FRS-R score and slope
was not affected by pioglitazone (p=0.66, Figure 3), and this was
also the case for quality of life and slow vital capacity (not shown).
The incidence of tracheotomy during the study period was
unchanged by pioglitazone (pioglitazone: 6.4%, placebo: 4.6%,
p=0.54). So was the incidence of NIV (pioglitazone: 20.2%,
placebo: 26.6%, p=0.28).
Adverse Events
Pioglitazone was well tolerated and most adverse events were
due to ALS disease progression, e.g. dysphagia, dyspnoea or
respiratory failure rather than to pioglitazone treatment, e.g.
oedema (table 2).
Discussion
In this randomized clinical trial, we could not show that
pioglitazone is a valid therapeutic option for ALS patients under
riluzole.
A number of clinical trials have been performed in ALS since
the positive trial of riluzole (Table S1 and references therein) [1].
Pioglitazone in ALS
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Except the recent small trial on dexpramipaxole [20], these trials
were all negative. Most of them were based on preclinical results
obtained in SOD1 mouse models that were either single studies in
animals, that have not been reproduced by other laboratories
(creatine [21,22], celecoxib [21,22,23]), or controversial studies
(lithium [24,25,26], IGF-1 [27,28,29]) (Table S1 and references
therein). To our knowledge, only minocycline [30,31,32] and
pioglitazone [5,6] have been shown to display protection in
mutant SOD1 mice by at least two independent laboratories and
have been tested in clinical trials (this study and [33]). These
disappointing results claim strongly for the generation of
alternative models of ALS. Indeed, the recent identification of
new genetic causes of ALS, in particular intronic expansions in the
Chr9 ORF 72 gene that account for more than 30% of familial
ALS, and a subset of sporadic ALS [34,35], could provide
unvaluable alternative preclinical models. Mutant SOD1 mice
currently represent the only animal model that reliably reproduces
the phenotype of ALS patients, but one should keep in mind that
SOD1 mutations only represent 2% of total ALS cases and do not
lead to TDP43/FUS/optineurin inclusions [36,37,38].
Figure 1. Study flow chart. The figure presents the numbers of participants who were randomly assigned, received pioglitazone or placebo, and
were analysed for the primary outcome.
doi:10.1371/journal.pone.0037885.g001
Table 1. Baseline characteristics of ALS patients.
Pioglitazone (n =109) Placebo (n =109) p value
Sex ratio (M/F) 63/46 71/38 0.33
Age at enrolment (years) 58.9 (10.6) 59.0 (10.4) 0.94
Site of onset (bulbar/spinal) 31/77 33/76 0.88
ALSFRS-R 37.5 (6.0) 37.0 (5.6) 0.51
SVC (%) 76.2 (16.6) 73.5 (15.4) 0.21
Body weight (kg) 72.8 (12.7) 74.1 (13.1) 0.46
BMI (kg/m2) 24.7 (3.8) 24.8 (3.7) 0.84
Glycaemia (mg/dL) 95.9 (13.3) 94.3 (14.8) 0.40
ASAT (U/L) 35.8 (12.1) 32.7 (11.3) 0.06
ALAT (U/L) 40.1 (17.9) 37.8 (21.3) 0.39
Blood pressure (systolic/diastolic, mm Hg) 133.2 (16.9)/83.0 (9.5) 138.5 (19.7)/87.0 (11.3) 0.07/0.02
Time from symptom onset to diagnosis (months) 9.6 (5.6) 8.7 (5.7) 0.25
Time from symptom onset to baseline screening
(months)
18.9 (8.6) 18.6 (9.0) 0.81
Values are indicated as mean (SD).
doi:10.1371/journal.pone.0037885.t001
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In the specific case of pioglitazone, three groups independently
reported protection by pioglitazone in mutant SOD1 mice [4,5,6].
The causes of the discrepancy between our negative clinical trial
result, and these promising preclinical trials are still elusive. First,
preclinical trials might have been inadequately designed since they
did not follow guidelines published after their completion [22,39].
In particular these guidelines now indicate to use at least 12
animals per group and per gender in a fully blinded manner [39].
Both studies used 7–12 mice per group for survival analysis, with
Schutz and collaborators [5] using only male mice while Kiaei and
collaborators [6] did not specify gender. Blinding, mandatory in
the new guidelines, was performed for one of the studies [5], but is
not mentionned for the other one. Second, the animal model
might be relevant for studying mechanisms, but of poor relevance
for preclinical trials. Third, we cannot completely exclude that
riluzole masks beneficial effects of pioglitazone, for instance
through modification of its brain disposal. Indeed, riluzole
interferes with P-glycoprotein efflux pomp and modifies brain
disposal of minocycline [40]. Thus, despite pioglitazone is known
to cross partially the blood brain barriers in mammals [41], it may
not have reached the concerned brain regions in concentrations
that would have allowed for neuroprotection due to interference
with riluzole. Of note, a poor translation of the dosage is unlikely
since doses used correspond to dosages recently described for their
efficacy in non-diabetic patients. However, preclinical trials have
been performed in mice before disease onset, and the time window
of pioglitazone administration might well be inadequate. Indeed,
PPARc and inflammation-promoting transduction pathways such
as NF-kB are antagonistic [42,43]. Given the robust inflammatory
reaction in the ventral horn of ALS patients [2] initiation of
treatment after several months of disease progression might be too
late. Our study illustrates the difficult translation from mouse
models to human ALS, and strongly claims for the generation of
new SOD1-independent animal models.
Summarizing, we could not find any protective effect of
pioglitazone in ALS patients under riluzole. The cause for this
failed clinical translation remains elusive.
Figure 2. Survival upon pioglitazone. Kaplan-Meier plot for
survival, the primary endpoint of the trial. Placebo-treated patients
are in blue and pioglitazone treated patients are in red. Ticks represent
censored patients. The shaded box indicates the first month of
treatment during which a stepwise increase in pioglitazone dosage
was performed. Numbers below the X axis indicate the number of
patients still alive (‘‘at risk’’, i.e. living and not censored) at entry, 6, 12
and 18 months after randomization.
doi:10.1371/journal.pone.0037885.g002
Figure 3. ALS-FRS upon pioglitazone. Total changes in ALS-FRS-R
score after initiation of the treatment. Placebo-treated patients are in
blue and pioglitazone treated patients are in red. The table below
indicates the number of patients (n) per time point. Error bars are
standard errors.
doi:10.1371/journal.pone.0037885.g003
Table 2. Adverse events.
Adverse event
Pioglitazone
(n =109)
Placebo
(n=109) p value
Dysphagia 32 (29.4%) 34 (31.2%) 0.88
Dyspnoea 35 (32.1%) 31 (28.4%) 0.66
Respiratory failure 33 (30.3%) 31 (28.4%) 0.88
Oedema 26 (23.9%) 18 (16.5%) 0.24
Depression 14 (12.8%) 13 (11.9%) 1.00
Weight loss 18 (16.5%) 9 (8.3%) 0.10
Constipation 15 (13.8%) 11 (10.1%) 0.53
Fatigue 12 (11.0%) 14 (12.8%) 0.83
Nasopharyngitis 13 (11.9%) 12 (11.0%) 0.83
Fall 11 (10.1%) 11 (10.1%) 1.00
Back pain 9 (8.3%) 10 (9.2%) 1.00
Musculoskeletal pain 9 (8.3%) 7 (6.4%) 0.80
Headache 7 (6.4%) 7 (6.4%) 1.00
Muscle spasms 7 (6.4%) 7 (6.4%) 1.00
Salivary hyper secretion 6 (5.5%) 8 (7.3%) 0.78
Sleep disorder 6 (5.5%) 8 (7.3%) 0.78
Bronchitis 7 (6.4%) 5 (4.6%) 0.77
Dizziness 8 (7.3%) 4 (3.7%) 0.37
Pain in extremity 10 (9.2%) 2 (1.8%) 0.03
Pneumonia 7 (6.4%) 5 (4.6%) 0.77
Urinary tract infection 9 (8.3%) 3 (2.8%) 0.13
Nausea 6 (5.5%) 5 (4.6%) 1.00
Pain 6 (5.5%) 5 (4.6%) 1.00
doi:10.1371/journal.pone.0037885.t002
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